- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in Oligonucleotide Therapeutics in Oncology
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 7, Pages 3295
Publisher
MDPI AG
Online
2021-03-25
DOI
10.3390/ijms22073295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
- (2020) Lei Sheng et al. NUCLEIC ACIDS RESEARCH
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy
- (2020) Annemieke Aartsma-Rus et al. Nucleic Acid Therapeutics
- Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis)
- (2020) Pramod N. Nehete et al. Frontiers in Aging Neuroscience
- Oligonucleotide–Polymer Conjugates: From Molecular Basics to Practical Application
- (2020) Fan Xiao et al. Topics in Current Chemistry
- Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
- (2020) Zhaoying Fu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).
- (2020) Anna M. Varghese et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorothioate modified oligonucleotide–protein interactions
- (2020) Stanley T Crooke et al. NUCLEIC ACIDS RESEARCH
- The powerful world of antisense oligonucleotides: From bench to bedside
- (2020) Anaïs M. Quemener et al. Wiley Interdisciplinary Reviews-RNA
- Targeting XIAP for Promoting Cancer Cell Death—The Story of ARTS and SMAC
- (2020) Ruqaia Abbas et al. Cells
- Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
- (2020) Simona D’Aguanno et al. Cells
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
- (2020) Alexandre J. Debacker et al. MOLECULAR THERAPY
- Advances in oligonucleotide drug delivery
- (2020) Thomas C. Roberts et al. NATURE REVIEWS DRUG DISCOVERY
- Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
- (2020) Karishma Dhuri et al. Journal of Clinical Medicine
- Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
- (2020) Prabir Kumar Kulabhusan et al. Pharmaceutics
- Nucleic Acid-Based Approaches for Tumor Therapy
- (2020) Simone Hager et al. Cells
- STAT3 and p53: Dual Target for Cancer Therapy
- (2020) Thu-Huyen Pham et al. Biomedicines
- c-MYB and DMTF1 in Cancer
- (2019) Elizabeth A. Fry et al. CANCER INVESTIGATION
- Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch
- (2019) Hongmei Xu et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond
- (2019) Anna M. Krichevsky et al. Neurotherapeutics
- Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties
- (2019) S. K. Miroshnichenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of Clusterin in cancer metastasis
- (2019) Mei Peng et al. Cancer Management and Research
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
- (2019) Bin Hou et al. DISEASE MARKERS
- Deoxyribozymes as Catalytic Nanotherapeutic Agents
- (2019) Levon M. Khachigian CANCER RESEARCH
- Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases
- (2019) Meenu Mehta et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia
- (2019) Michael Steurer et al. HAEMATOLOGICA
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
- (2019) Ghanbar Mahmoodi Chalbatani et al. International Journal of Nanomedicine
- Clinical development of targeted and immune based anti-cancer therapies
- (2019) N. A. Seebacher et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems
- (2019) Praful R. Nair Polymers
- Current Development of siRNA Bioconjugates: From Research to the Clinic
- (2019) Ivan V. Chernikov et al. Frontiers in Pharmacology
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
- (2019) Mariane H. Schleimann et al. EBioMedicine
- A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial
- (2019) David R. Spigel et al. ONCOLOGIST
- Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?
- (2019) Choi et al. Cancers
- The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: a molecular aspect
- (2019) Yingyu Dou et al. Journal of Ovarian Research
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy
- (2019) Tae Heung Kang et al. Journal for ImmunoTherapy of Cancer
- Targeting BCL-2 regulated apoptosis in cancer
- (2018) Kirsteen J. Campbell et al. Open Biology
- Harnessing albumin as a carrier for cancer therapies
- (2018) Ella N. Hoogenboezem et al. ADVANCED DRUG DELIVERY REVIEWS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- (2018) Mario Lacouture et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development
- (2018) Tao Wang et al. BIOTECHNOLOGY ADVANCES
- Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications
- (2018) JingJing Zhang Catalysts
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
- (2018) Bao T. Le et al. Molecular Therapy-Nucleic Acids
- Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes
- (2017) Shuaijian Ni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
- (2017) Evan Y. Yu et al. INVESTIGATIONAL NEW DRUGS
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
- (2017) Kim N Chi et al. LANCET ONCOLOGY
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
- (2017) Tomasz M Beer et al. LANCET ONCOLOGY
- Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
- (2017) Nico van Zandwijk et al. LANCET ONCOLOGY
- RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
- (2017) Xue-Hai Liang et al. MOLECULAR THERAPY
- Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
- (2017) Valentina Sardone et al. MOLECULES
- The chemical evolution of oligonucleotide therapies of clinical utility
- (2017) Anastasia Khvorova et al. NATURE BIOTECHNOLOGY
- Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
- (2017) Naoki Iwamoto et al. NATURE BIOTECHNOLOGY
- Cellular uptake and trafficking of antisense oligonucleotides
- (2017) Stanley T Crooke et al. NATURE BIOTECHNOLOGY
- MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
- (2017) Rajesha Rupaimoole et al. NATURE REVIEWS DRUG DISCOVERY
- A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
- (2017) Andrew H. Ko et al. ONCOLOGIST
- Effect of Chemical Modifications on Aptamer Stability in Serum
- (2017) Christina Kratschmer et al. Nucleic Acid Therapeutics
- Theranostic DNAzymes
- (2017) Wenhu Zhou et al. Theranostics
- Transforming growth factor-β: A therapeutic target for cancer
- (2017) Sulsal Haque et al. Human Vaccines & Immunotherapeutics
- siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
- (2017) Katyayani Tatiparti et al. Nanomaterials
- Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- (2016) Francis A.S. Lee et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Adapting conventional cancer treatment for immunotherapy
- (2016) Jian Qiao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The delivery of therapeutic oligonucleotides
- (2016) Rudolph L. Juliano NUCLEIC ACIDS RESEARCH
- In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies
- (2016) Farhana Lipi et al. RNA Biology
- Cellular uptake and intracellular trafficking of oligonucleotides
- (2015) R.L. Juliano et al. ADVANCED DRUG DELIVERY REVIEWS
- DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes
- (2015) Alesya A Fokina et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Oligonucleotide therapeutics: chemistry, delivery and clinical progress
- (2015) Vivek K Sharma et al. Future Medicinal Chemistry
- Drug-drug plasma protein binding interactions of ivacaftor
- (2015) Elena K. Schneider et al. JOURNAL OF MOLECULAR RECOGNITION
- Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy
- (2015) B. Lelj-Garolla et al. MOLECULAR CANCER THERAPEUTICS
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem
- (2015) Lei Xie et al. Frontiers in Pharmacology
- siRNA Versus miRNA as Therapeutics for Gene Silencing
- (2015) Jenny K W Lam et al. Molecular Therapy-Nucleic Acids
- Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
- (2015) Sebastien A. Burel et al. Nucleic Acid Therapeutics
- DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas
- (2014) Wei-Hua Liao et al. BMC CANCER
- Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- (2014) A. Ruzsa et al. INVESTIGATIONAL NEW DRUGS
- Regulation of microRNA biogenesis
- (2014) Minju Ha et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
- (2014) Julia Scheiermann et al. VACCINE
- Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
- (2014) Hongguang Sun et al. Molecular Therapy-Nucleic Acids
- Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma
- (2013) G. Reid et al. ANNALS OF ONCOLOGY
- The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization
- (2013) J. Hoellenriegel et al. BLOOD
- A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
- (2013) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
- (2013) Jonathan E. Rosenberg et al. INVESTIGATIONAL NEW DRUGS
- Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression
- (2013) Yu Wang et al. JOURNAL OF CHEMOTHERAPY
- Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
- (2013) Jens Dannull et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)
- (2013) Eun-Ae Cho et al. LANCET
- Defibrotide: Properties and clinical use of an old/new drug
- (2013) R. Pescador et al. VASCULAR PHARMACOLOGY
- First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
- (2013) Josep Tabernero et al. Cancer Discovery
- Role of STAT3 in Cancer Metastasis and Translational Advances
- (2013) Mohammad Zahid Kamran et al. Biomed Research International
- An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
- (2012) Phuong Khanh Morrow et al. CANCER
- Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
- (2012) Glen F. Deleavey et al. CHEMISTRY & BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
- (2011) C. Manegold et al. ANNALS OF ONCOLOGY
- Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
- (2011) Karl-Hermann Schlingensiepen et al. CANCER SCIENCE
- Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Vera Hirsh et al. JOURNAL OF CLINICAL ONCOLOGY
- The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia
- (2011) J Dürig et al. LEUKEMIA
- Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
- (2011) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- MicroRNA and drug resistance
- (2010) J Ma et al. CANCER GENE THERAPY
- Insights into RNA/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex
- (2010) Pradeep S. Pallan et al. CELL CYCLE
- MicroRNA: Biogenesis, Function and Role in Cancer
- (2010) Leigh-Ann MacFarlane et al. CURRENT GENOMICS
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
- (2009) Jörg Vollmer et al. ADVANCED DRUG DELIVERY REVIEWS
- Bcl2 family proteins in carcinogenesis and the treatment of cancer
- (2009) Anna Frenzel et al. APOPTOSIS
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
- (2009) Jeffrey S. Weber et al. CANCER
- Treatment of malignant gliomas with TGF-β2 antisense oligonucleotides
- (2009) Peter Hau et al. Expert Review of Anticancer Therapy
- A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides
- (2009) Su Young Oh et al. MOLECULES AND CELLS
- Comparing In Vitro and In Vivo Activity of 2′-O-[2-(Methylamino)-2-oxoethyl]- and 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
- (2008) Thazha P. Prakash et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now